Literature DB >> 1728856

Mitotically active leiomyomas of the uterus.

R A Prayson1, W R Hart.   

Abstract

A series of 15 uterine smooth muscle tumors with histologic features of typical leiomyomas, except for the presence of mitotic activity exceeding 4 mitotic figures per 10 high-power fields (HPF), were studied. The patients' ages ranged from 25 to 50 years (median, 37 years). At least 60% of the tumors were submucosal. The maximum dimension of the tumors ranged from 1.3 to 8.0 cm (median, 3.8 cm). On gross examination, the tumors appeared to be generally unremarkable. By definition, none had cytologic atypia. Mitosis counts were performed in the most active areas by two methods. Counts ranged from 5 to 15 mitotic figures per 10 HPFs when the highest count in any single set of 10 HPFs was recorded (method A) and from 4.2 to 10.2 mitotic figures per 10 HPFs when the average count from 50 consecutive HPFs was determined (method B). Treatment included hysterectomy in eight patients, myomectomy followed by hysterectomy in one, and myomectomy only in six. All but one patient with evaluable endometria were in the secretory phase of the menstrual cycle. Follow-up periods ranged from 6 months to 10.5 years (mean, 2.5 years; median, 2.1 years). None developed local recurrences or metastases. The benign clinical behavior of such tumors warrants the designation of mitotically active leiomyoma rather than smooth muscle tumor of uncertain malignant potential or low-grade leiomyosarcoma.

Entities:  

Mesh:

Year:  1992        PMID: 1728856     DOI: 10.1093/ajcp/97.1.14

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

Review 2.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  Endocrine disruptor exposure during development increases incidence of uterine fibroids by altering DNA repair in myometrial stem cells.

Authors:  Lauren E Prusinski Fernung; Qiwei Yang; Daitoku Sakamuro; Alpana Kumari; Aymara Mas; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2018-10-01       Impact factor: 4.285

4.  MED12 exon 2 mutations in histopathological uterine leiomyoma variants.

Authors:  Netta Mäkinen; Pia Vahteristo; Kati Kämpjärvi; Johanna Arola; Ralf Bützow; Lauri A Aaltonen
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

5.  Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.

Authors:  Saketh R Guntupalli; Pedro T Ramirez; Matthew L Anderson; Michael R Milam; Diane C Bodurka; Anais Malpica
Journal:  Gynecol Oncol       Date:  2009-04-02       Impact factor: 5.482

6.  Rodent model of reproductive tract leiomyomata. Clinical and pathological features.

Authors:  J I Everitt; D C Wolf; S R Howe; T L Goldsworthy; C Walker
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

7.  Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.

Authors:  Netta Mäkinen; Kati Kämpjärvi; Norma Frizzell; Ralf Bützow; Pia Vahteristo
Journal:  Mol Cancer       Date:  2017-06-07       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.